Australia's Amplia Therapeutics jumps most in 3 yrs on upbeat cancer drug trial results
** Shares of Amplia Therapeutics ATX.AX rise as much as
46.8% to A$0.091, posting their biggest intraday percentage
gain since June 2, 2021
** Drug developer posts positive results from the clinical
trial of its pancreatic cancer drug narmafotinib
** Says results show at least a 30% decrease in the overall
size of tumour, and no new tumour lesions over two months in
three patients
** About 1.3 mln shares change hands, compared with the
30-day average volume of around 300,000
** Stock up 5.5% YTD, including session's moves
(Reporting by Aaditya Govind Rao in Bengaluru)
((Aaditya.govindrao@thomsonreuters.com;))
Recent news on Amplia Therapeutics
See all newsBrief: Amplia Therapeutics Signs Collaboration And Supply Agreement With Lilly
Australia's Amplia rises to 4-month high on Eli Lilly cancer drug trial collaboration
Brief: Amplia Therapeutics Says Warwick Tong Will Retire As Board Chairman
Brief: Amplia Therapeutics Reports Four Additional Complete Responses And Improved Overall Survival Data In Accent Pancreatic Cancer Trial
Brief: Amplia Therapeutics Requests Trading Halt Pending Clinical Trial Results Announcement